✦ LIBER ✦

Review of the Evidence for the Clinical Utility of Lipoprotein-Associated Phospholipase A2 as a Cardiovascular Risk Marker

✍ Scribed by Marshall A. Corson; Peter H. Jones; Michael H. Davidson

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lipoprotein associated phospholipase A2:

✍ Kenneth J. Colley; Robert L. Wolfert; Michael E. Cobble 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 656 KB

The role of lipoprotein-associated phosp

✍ Salim S. Virani; Vijay Nambi 📂 Article 📅 2007 🏛 Current Science Inc. 🌐 English ⚖ 141 KB

The role of lipoprotein-associated phosp

✍ Kota J. Reddy; Manmeet Singh; Joey R. Bangit; Richard R. Batsell 📂 Article 📅 2009 🏛 Elsevier 🌐 English ⚖ 382 KB

Lipoprotein-associated phospholipase A2

✍ Fitzpatrick, Annette L.; Irizarry, Michael C.; Cushman, Mary; Jenny, Nancy S.; C 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 564 KB

Lipoprotein-associated phospholipase A2

✍ Annette Fitzpatrick; Michael Irizarry; Mary Cushman; Nancy Jenny; Gloria Chi; Ca 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Lipoprotein-Associated Phospholipase A2:

✍ Richard B. Lanman; Robert L. Wolfert; James K. Fleming; Allan S. Jaffe; William 📂 Article 📅 2006 🏛 Le Jacq Communications, Inc. 🌐 English ⚖ 201 KB